BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.16//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250317T130000
DTEND;TZID=Europe/Stockholm:20250317T140000
DTSTAMP:20260308T075531
CREATED:20250303T110411Z
LAST-MODIFIED:20250303T110412Z
UID:182354-1742216400-1742220000@www.scilifelab.se
SUMMARY:PULSE Challenge: Selection and screening of antibody based drugs
DESCRIPTION:This presentation will provide an overview of the selection and screening processes\, as well as future challenges for antibody-based drugs. It will be exemplified with data from one of Alligator Bioscience’s bispecific antibody drug candidates\, ATOR-4066. ATOR-4066 is a novel bispecific antibody constructed in the RUBY™ format using Alligator Bioscience’s Neo-X-Prime platform. It targets the tumor-associated antigen CEA (CEACAM5) on tumor cells and CD40 on myeloid cells. ATOR-4066 is designed to induce efficient CEA-conditional activation of myeloid cells\, facilitate the uptake of neoantigen-containing tumor-derived material\, and subsequently drive the cross-priming of tumor-specific T cells\, resulting in long-lasting anti-tumor activity. \n\n\n\nThe seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE\, that will train 48 future leaders in life sciences. The program focuses on innovative\, fundamental and translational research carried out in supportive and diverse academic and industrial environments\, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE \n\n\n\n\n\n\n\nOn-line event via Zoom \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\nPresenter: Dr Peter Ellmark\, PhDChief Scientific OfficerAlligator bioscience\, Lund\, Sweden \n\n\n\nAbstract:Antibody-based drugs have revolutionized the treatment landscape for numerous serious conditions\, with a global market size exceeding $250 billion. The success of these drugs can be attributed to their high specificity and versatility. Critical to the successful development of antibody-based drugs is the appropriate selection and screening methodology\, which ensures that drug candidates meet all key criteria for successful development. \n\n\n\nA short speaker biography:Peter Ellmark joined Alligator Bioscience in 2008 and serves as Chief Scientist. He holds a PhD and an adjunct professorship in Immunotechnology at Lund University and has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies\, in particular CD40 and 4-1BB targeting therapies\, for tumor directed immunotherapy of cancer.
URL:https://www.scilifelab.se/event/pulse-challenge-selection-and-screening-of-antibody-based-drugs/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2025/02/Bild1-e1770905208628.png
END:VEVENT
END:VCALENDAR